Infections, Respiratory Tract Clinical Trial
Official title:
Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparation of Cephalexin 125 mg/ 5 ml (Ceporex® GlaxoSmithKline México, S.A. de C.V. vs. Keflex®, Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers
The objective of this study was to confirm if two formulations of cephalexin suspension are
bioequivalent.
Test product was Ceporex® (125 mg Cephalexin / 5 ml; GlaxoSmithKline) and reference product
Keflex® (125 mg Cephalexin / 5 ml; Eli Lilly). The single dosage was 20 ml of suspension.
The study was prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 28 healthy volunteers, both genders, adults between 18-50
years.
The comparative bioavailability of the two formulations was evaluated based in statistical
comparisons of relevant pharmacokinetic parameters, obtained from data of drug
concentrations in blood.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02202187 -
A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02257398 -
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01706315 -
This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02000765 -
A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
|
Phase 1 | |
Completed |
NCT04600752 -
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
|
Phase 4 | |
Terminated |
NCT01292213 -
A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom
|
N/A | |
Completed |
NCT01772238 -
Bioequivalence Study of an Amoxicillin-Clavulanic
|
Phase 1 | |
Completed |
NCT01615796 -
Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses
|
Phase 1 | |
Completed |
NCT02169583 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01353768 -
Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study
|
N/A | |
Completed |
NCT01767571 -
Bioequivalence Study of Cephalexin Suspension 250
|
Phase 1 | |
Completed |
NCT01510938 -
Probiotics in Respiratory Tract Infections in Children
|
Phase 2 | |
Completed |
NCT00354965 -
Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients
|
Phase 1 | |
Completed |
NCT02688361 -
A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution
|
Phase 1 | |
Withdrawn |
NCT02678234 -
An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu
|
Phase 3 | |
Withdrawn |
NCT02730364 -
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
|
Phase 3 | |
Completed |
NCT01767584 -
Bioequivalence Study of Cephalexin Tablets 1g
|
Phase 1 |